**Maternal Medicine CSG Meeting Notes**

**Friday 7th December 2012, RCOG**

1. Present: Prof Lucilla Poston, Ms Jane Brewin, Dr Shiao Chan, Dr Lucy Chappell, Dr Fiona Denison, Dr Jenny Myers, Professor Steve Robson, Professor Andrew Shennan, Dr Louise Webster

Apologies: Prof Fionnuala McAuliffe, Dr Dharmintra Pasupathy, Prof Peter Brocklehurst, Prof Shakila Thangaratinam, Asma Khalil, Prof Helen Spiby, Dr Ian Crocker, Dr Jason Waugh, Dr Catherine Nelson-Piercy

1. Matters arising from previous meeting
2. As Chair of the MM CSG, LP presented the HTA vignettes to the RCOG Research Committee; they have now been sent to the consumers’ forum for input and the Chair of the RCOG Academic Board will then forward four (2 obstetric, 2 gynaecology) to the HTA. The process had encouraged communication and collaboration between various groups, particularly around diabetes in pregnancy. Action: call to be arranged with David McCance and interested parties. J Myers will report back from diabetes and pregnancy study group.
3. WISP study: Dr Shiao Chan presented the WISP study outline, which has been selected for full application to the HTA (protocol previously circulated to members) and members commented on the design. The MM CSG ratified the application. Cost approximately £3.1M.LP to write letter of CSG support
4. Prof Robson (Chair, RCOG Academic Board) reported that funding was being made available for a research assistant for the Research Committee to synthesise recommendations for future research (i.e. unanswered questions) from global literature such as guidelines. This will then be circulated to CSG chairs for discussion and would be updated once a year. Funding had also been secured for long-term clerical support for the CSG leads (2 days a week from January 2013). LP welcomed this news and thanked Prof Robson.
5. Update on planned studies
   1. Two competitive applications are being submitted to HTA in January 2013 for the timing of delivery trial for pre-eclampsia at 34 to 37 weeks. There was discussion regarding the difference between commissioned calls (where there may be competition) and responsive calls (where there is no competition).
   2. PARROT: Revealed vs. concealed PlGF in women with suspected pre-eclampsia (full application for submission in January 2013).

Update on ongoing studies

1. UPBEAT: LP updated that almost 800 women had been recruited and the trial was going well, with a no cost extension.
2. IMPROVED: 1st trimester prediction of pre-eclampsia: LK not available to report. Keele recruiting in UK.
3. TEST: 1st trimester prediction of pre-eclampsia with aspirin intervention in those identified at increased risk: FM not available to report.
4. FACT: folate supplementation to prevent pre-eclampsia. Prof Robson reported that contract signed and ethics approval imminent. Provisional start date: 1st April 2013. LP and SR were planning a mechanistic study alongside to be funded separately.
5. New study idea: Dr Shaio Chan presented briefly on the topic of an RCT of thyroxine vs. placebo of subclinical hypothyroidism with primary outcome of pregnancy loss.
6. Date of next meeting: Provisional: Thursday 25th April (lunchtime; 12-1pm) at BMFMS, Dublin. Room details TBC.